Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease-Reference-Cited by-同舟云学术

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

Published:2018-04 Issue:5 Volume:154 Page:1343-1351.e1
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

D’Haens Geert^ORCID,Vermeire Severine,Lambrecht Guy,Baert Filip,Bossuyt Peter,Pariente Benjamin,Buisson Anthony,Bouhnik Yoram,Filippi Jérôme,vander Woude Janneke,Van Hootegem Philippe^ORCID,Moreau Jacques,Louis Edouard,Franchimont Denis,De Vos Martine,Mana Fazia,Peyrin-Biroulet Laurent,Brixi Hedia,Allez Matthieu,Caenepeel Philip,Aubourg Alexandre,Oldenburg Bas,Pierik Marieke^ORCID,Gils Ann,Chevret Sylvie,Laharie David,Détré Patricia,Bertin Marie-Jo,Williams Sabrina

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference23 articles.

1. Infliximab, azathioprine, or combination therapy for Crohn's disease;Colombel;N Engl J Med,2010

2. Adalimumab induces deep remission in patients with Crohn's disease;Colombel;Clin Gastroenterol Hepatol,2014

3. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial;D'Haens;Lancet,2008

4. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease;Rutgeerts;Gastrointest Endosc,2006

5. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease;Shah;Aliment Pharmacol Ther,2016

Cited by 260 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enteric-coated cerium dioxide nanoparticles for effective inflammatory bowel disease treatment by regulating the redox balance and gut microbiome;Biomaterials;2025-03

2. How comparative studies can inform treatment decisions for Crohn’s disease;Expert Opinion on Biological Therapy;2024-08-12

3. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

4. Evaluating the Efficacy of Infliximab in Inflammatory Bowel Disease: A Systematic Review of the Literature;Cureus;2024-08-01

5. Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study;Gastroenterología y Hepatología (English Edition);2024-08